Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Hao Y, Yang HS, Karbaschi M, Racine-Brzostek SE, Li P, Zuk R, et al. Measurements of SARS-CoV-2 antibody dissociation rate constant by chaotrope-free biolayer interferometry in serum of COVID-19 convalescent patients. Biosens Bioelectron. 2022;209:114237.

Temkin SM, Smeltzer MP, Dawkins MD, Boehmer LM, Senter L, Black DR, et al. Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations. Cancer. 2022;128(4):654-664.

Wang X, Barrera C, Bera K, Viswanathan VS, Azarianpour-Esfahani S, Koyuncu C, et al. Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors. Sci Adv. 2022;8(22):eabn3966.

Argani P, Boyraz B, Oliva E, Matoso A, Gross J, Fridman E, et al. GLI1 Gene Alterations in Neoplasms of the Genitourinary and Gynecologic Tract. Am J Surg Pathol. 2022;46(5):677-687.

Slocum CC, Park HJ, Baek I, Catalano J, Wells MT, Liechty B, et al. Towards a single-assay approach: a combined DNA/RNA sequencing panel eliminates diagnostic redundancy and detects clinically-relevant fusions in neuropathology. Acta Neuropathol Commun. 2022;10(1):167.

Greenberg J, Limberg J, Verma A, Kim D, Chen X, Lee YJ, et al. Metastatic pancreatic neuroendocrine tumors feature elevated T cell infiltration. JCI Insight. 2022;7(23).

Kim S, Au CM, Bin Jamalruddin MA, Abou-Ghali NE, Mukhtar E, Portella L, et al. AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer. Elife. 2022;11.

Nassar AH, Adib E, Alaiwi SA, Zarif TE, Groha S, Akl EW, et al. Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. Cancer Cell. 2022;40(10):1161-1172.e5.

Lebowitz E, Kim JS, Magro C. Reactive arthritis following COVID-19 vaccination with BNT162b2. JAAD Case Rep. 2022;24:108-111.

Yuen CA, Hsu J-, Van Besien K, Reshef R, Iwamoto FM, Haggiagi A, et al. Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement and/or HIV: A Multicenter Experience. J Immunother. 2022;45(5):254-262.